Clinical trial
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid…
NCT00101816 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00101816 |
|---|---|
| Title | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate |
| Official title | A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Blast Crisis |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 124 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Jan 14, 2005 |
| Last update posted | Aug 10, 2010 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, Norway and 8 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: